Drug intelligence / Profile preview

MIC1445

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC1445 is a small molecule therapeutic candidate currently in preclinical development by Micar Innovation for the treatment of psoriasis. Discovered through Micar Innovation's proprietary drug discovery platform, the compound is part of a pipeline of wholly-owned assets. As of early 2024, the specific biological target and mechanism of action for MIC1445 remain undisclosed by the developer, though it is characterized as a small molecule intended for dermatological applications.

Beyond the preview

Go deeper on MIC1445.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC1445.

Explore the full profile